Financing the Plan

Accelerating HIV vaccine research requires the infusion of new resources, as well as a realignment of existing funds. In 2006, total global investment in preventive HIV vaccine R&D was approximately US$933 million, a 23% increase over 2005 funding levels. This growth is due to new research initiatives funded through the US National Institutes of Health, the European Commission, and the Bill and Melinda Gates Foundation.

The Enterprise calls on governments and other funders of HIV vaccine research to increase their financial commitments, and to target current and new resources to the priority areas in the scientific strategic plan. It is critical that new funders come on board as well, and that private pharmaceutical and biotechnology companies increase their own investments in HIV vaccine research.

Financing HIV Vaccine Research and Development

Chart of Public, Philanthripic, and Commercial Funding for HIV Vaccinnes in 2006Chart of Non-Commercial Funding Allocations For Preventative HIV-Vaccine R&D By Category in 2006

Source: HIV Vaccines and Microbicides Resource Tracking Working Group 2007 Report

All Content ©2005 - 2008 Global HIV Vaccine Enterprise